Bruce Liu

The region is moving to the forefront in integrating therapeutic innovation.

Is it possible to win in Asia’s private market?

The three key themes likely to shape pharma fortunes in 2024.

Effective engagement—from research to reimbursement—is key.

Attempts to capitalize on the region’s vibrant R&D scene are heating up.

The time is ripe to double down on local “market-fit” capabilities.

Despite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.

An ecosystem perspective is the first step.

Global go-to-market strategies in region require a revamped gameplan.

The 2022 National Reimbursement Drug List will see more pressures for new inclusions on the one hand, and more certainties for renewals on the other. At the same time, the process is becoming more interactive and transparent.

The rare disease market in China can be summed up in three words: Exciting, challenging, and fast evolving. As such it’s quite a complicated space that requires a careful and strategic approach. In this article experts from Simon-Kucher discuss how best to navigate this landscape to reap the many opportunities available.

Continent has shed its ‘emerging’ status on world biopharma stage.

Its use enables key processes such as early access, regulatory approval, and reimbursement listing.

Exploring the market’s emergence on the global stage.

China‘s 2021 National Reimbursement Drug List (NRDL) results are finally out, and this year features another major expansion of the NRDL formulary, with ongoing emphasis on innovations and some much anticipated breakthroughs in rare disease drug inclusions.

To maximize the potential of innovative therapies in the Chinese market, it’s important to have a holistic view of the full range of options and levers, prioritize and sequence the ones with the highest impacts, and develop an integrated strategy tailored to address the country’s unmet needs.